Regulation of MD-2 function and expression
MD-2 功能和表达的调节
基本信息
- 批准号:7454954
- 负责人:
- 金额:$ 34.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-06-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAgonistAlbuminsAntibodiesBindingBinding ProteinsBiologicalCD14 geneCalciumCell surfaceCellsComplexCoupledCouplingDevelopmentEndothelial CellsEndotoxinsEpithelial CellsEpitheliumExposure toFresh TissueGoalsGram-Negative BacteriaHanks Balanced Salt SolutionHumanImmuneImmune responseInfectionInflammatory ResponseInvadedLabelLeadLinkLipid ALipopolysaccharidesMagnesiumMediator of activation proteinMembraneMessenger RNAMolecularMonitorMonoclonal AntibodiesNeisseriaPathologyPropertyProteinsRecombinantsRegulationResearch PersonnelRoleSignal TransductionStructureSurfaceTLR4 geneTherapeuticTissuesToll-Like Receptor 2Toll-like receptorsTranscriptional ActivationUmbilical veinUp-Regulationairway epitheliumbasebronchial epitheliumcytokineextracellularimprovedinsightkidney celllipooligosaccharidelipopolysaccharide-binding proteinmolecular recognitionnovelprogramsprophylacticprotein Eresponsetoll-like receptor 4
项目摘要
DESCRIPTION (provided by applicant): Highly sensitive host responses to endotoxin (E) are needed for optimal defense against many species of invading Gram-negative bacteria (GNB) but can also lead to significant host pathology when exposure to endotoxin is not adequately controlled. Maximum sensitivity of E signaling requires the ordered interaction of E with several extracellular and cell surface host proteins, including: lipopolysaccharide (LPS)-binding protein (LBP), CD14, MD-2 and Toll-Like Receptor (TLR) 4. Recent observations, including our own, indicate an essential role for MD-2, linking E recognition initiated by LBP and CD14 to activation of TLR4 and determining, at least in certain settings (e.g. airway epithelium), cellular responsiveness to E.
The long-term goals of this project are to better understand the molecular basis of innate immune recognition of E and of the coupling of E recognition to induction of pro-inflammatory responses. Our immediate focus will be the structure, function and expression of MD-2, including: 1) further characterization of the structural determinants of E-MD-2 interactions; 2) identification of molecular properties of E:MD-2 complexes required either for potent agonist or antagonist function; and 3) characterization of mechanism(s) regulating MD-2 expression in human airway epithelial cells.
We will use metabolically labeled and chromatographically purified E and recombinant E-binding proteins (LBP, sCD14 and MD-2) to analyze protein-E interactions at low, patho-physiologically relevant E concentrations and to preparatively purify protein:E complexes for further structural and functional analyses. MD-2 expression will be monitored by mRNA and protein analyses of fresh tissue and primary cultures of human bronchial epithelium to identify mediators and mechanisms of regulation of MD-2 expression.
These studies should yield novel insights concerning the structural determinants of host-E interactions important in innate immune recognition and response to invading GNB. A better understanding of the structure, function and expression of MD-2 should improve understanding of the regulation of host responsiveness to E and could pave the way for development of compounds that, by modulating cellular responses to E, may have prophylactic and/or therapeutic applications.
描述(由申请方提供):需要对内毒素(E)高度敏感的宿主反应,以最佳防御许多种入侵的革兰氏阴性菌(GNB),但当暴露于内毒素未得到充分控制时,也可能导致显著的宿主病理学。E信号传导的最大灵敏度需要E与几种细胞外和细胞表面宿主蛋白的有序相互作用,包括:脂多糖(LPS)结合蛋白(LBP),CD 14,MD-2和Toll样受体(TLR)4。最近的观察,包括我们自己的,表明MD-2的重要作用,连接E识别启动LBP和CD 14激活TLR 4和确定,至少在某些设置(如气道上皮),细胞对E。
该项目的长期目标是更好地理解E的先天免疫识别的分子基础以及E识别与促炎反应诱导的耦合。我们目前的重点将是MD-2的结构、功能和表达,包括:1)进一步表征E-MD-2相互作用的结构决定因素; 2)鉴定E:MD-2复合物的分子特性,这些特性是有效的激动剂或拮抗剂功能所必需的; 3)表征MD-2在人气道上皮细胞中表达的调节机制。
我们将使用代谢标记和色谱纯化的E和重组E结合蛋白(LBP,sCD 14和MD-2),以分析蛋白质-E相互作用在低,病理生理相关的E浓度和纯化蛋白质:E复合物进一步的结构和功能分析。将通过人支气管上皮的新鲜组织和原代培养物的mRNA和蛋白质分析来监测MD-2表达,以鉴定MD-2表达的调节介质和机制。
这些研究应产生新的见解有关的结构决定因素主机E相互作用的先天免疫识别和入侵GNB的反应很重要。更好地了解MD-2的结构,功能和表达,应提高对宿主对E的反应性调节的理解,并可能为开发通过调节细胞对E的反应,可能具有预防和/或治疗应用的化合物铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JERROLD P WEISS其他文献
JERROLD P WEISS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JERROLD P WEISS', 18)}}的其他基金
MOBILIZATION AND DELIVERY OF LIPOOLIGOSACCHARIDES TO HOST TARGETS
脂寡糖的动员和递送至宿主靶标
- 批准号:
6653280 - 财政年份:2002
- 资助金额:
$ 34.3万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 34.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 34.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 34.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




